Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raynaud's phenomenon.

Ariane Herrick1

  • 1Rheumatic Diseases Centre, University of Manchester, Salford Royal NHS Foundation Trust, Stott Lane, Salford M6 8HD, UK. ariane.herrick@manchester.ac.uk

Current Treatment Options in Cardiovascular Medicine
|March 8, 2008
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The 2024 British Society for Rheumatology guideline for management of systemic sclerosis-executive summary.

Rheumatology (Oxford, England)·2024
Same author

The 2024 British Society for Rheumatology guideline for management of systemic sclerosis.

Rheumatology (Oxford, England)·2024
Same author

Management of systemic sclerosis: British Society for Rheumatology guideline scope.

Rheumatology advances in practice·2023
Same author

An MIF Promoter Polymorphism Is Associated with Susceptibility to Pulmonary Arterial Hypertension in Diffuse Cutaneous Systemic Sclerosis.

The Journal of rheumatology·2017
Same author

Analysis of ATP8B4 F436L Missense Variant in a Large Systemic Sclerosis Cohort.

Arthritis & rheumatology (Hoboken, N.J.)·2017
Same author

Brief Report: IRF4 Newly Identified as a Common Susceptibility Locus for Systemic Sclerosis and Rheumatoid Arthritis in a Cross-Disease Meta-Analysis of Genome-Wide Association Studies.

Arthritis & rheumatology (Hoboken, N.J.)·2016
Same journal

An Update on the Role of Renal Artery Denervation in the Treatment of Hypertension.

Current treatment options in cardiovascular medicine·2026
Same journal

Advancements and Challenges in Contemporizing Care for Adult Patients with Congenital Heart Disease and Advanced Heart Failure: An Update on Application of Modern Heart Failure Technologies.

Current treatment options in cardiovascular medicine·2026
Same journal

Evolving Decongestion Strategies in the Management of Acute Heart Failure.

Current treatment options in cardiovascular medicine·2025
Same journal

Advanced Electroanatomic Mapping: Current and Emerging Approaches.

Current treatment options in cardiovascular medicine·2025
Same journal

Metabolic Reprogramming in Heart Failure: From Energy Starvation to Therapeutic Targets.

Current treatment options in cardiovascular medicine·2025
Same journal

Drug-Coated Balloons for Coronary Artery Disease: From Theory to Practice.

Current treatment options in cardiovascular medicine·2025
See all related articles

Treatment for Raynaud

Area of Science:

  • Vascular Medicine
  • Rheumatology
  • Pharmacology

Background:

  • Raynaud's phenomenon (RP) presents with varying severity and underlying causes.
  • Primary RP often responds to conservative management and calcium channel blockers.
  • Secondary RP, particularly in connective tissue diseases like systemic sclerosis, can be refractory and lead to severe complications.

Purpose of the Study:

  • To review current and emerging treatment strategies for Raynaud's phenomenon.
  • To emphasize management approaches for challenging cases, including those associated with systemic sclerosis.
  • To explore novel therapeutic targets based on updated pathogenetic insights.

Main Methods:

  • Review of existing literature on Raynaud's phenomenon management.

Related Experiment Videos

  • Focus on treatment principles including trigger avoidance, general measures, pharmacotherapy, and surgical options.
  • Inclusion of research on new therapeutic pathways.

    • Main Results:

    • General measures and calcium channel blockers are effective for primary RP.
    • Secondary RP, especially in systemic sclerosis, presents significant treatment challenges.
    • Emerging treatments target endothelin-1 and nitric oxide pathways.

    Conclusions:

    • Treatment of Raynaud's phenomenon requires individualized approaches based on severity and etiology.
    • Management strategies encompass conservative measures, pharmacotherapy, and, rarely, surgery.
    • Novel therapeutic avenues are being developed for refractory cases of Raynaud's phenomenon.